Alisol B 23-acetate

Alisol B 23-acetate is an orally active prototerpane-type triterpenoid. Alisol B 23-acetate can be isolated from Alisma orientalis. Alisol B 23-acetate induces Apoptosis, promotes ROS generation, downregulates CDK4/6, MMP-2/9, upregulates cleaved PARP, activates FXR and inhibits Syk. Alisol B 23-acetate has anti-inflammatory and hepatoprotective activities. Alisol B 23-acetate protects the kidney from ischemia-reperfusion injury. Alisol B 23-acetate has anticancer activity against ovarian cancer, colon cancer, lung cancer, and gastric cancer. Alisol B 23-acetate can be used in the study of atherosclerosis and allergic asthma^{[1][2][3][4][5][6][7][8][9][10][11][12][13][14]}. In Vitro:Alisol B 23-acetate (2.5-20 µM; 24-48 h) significantly inhibits cell viability, induces G₁ phase cell cycle arrest and apoptosis, suppresses migration and invasion in ovarian cancer cell lines A2780, A2780/Taxol, and HEY^[1].
Alisol B 23-acetate (1-100 µM) reverses P-glycoprotein (P-gp)-mediated multidrug resistance in HepG2-DR and K562-DR cells^[2].
Alisol B 23-acetate (5-20 µM; 6-24 h) induces autophagic-dependent apoptosis in human colon cancer cells (HCT116 and SW620) via ROS generation and JNK activation^[3].
Alisol B 23-acetate (20-80 µM; 24 h) improves free fatty acid (FFA)-induced lipid metabolism disorders in L02 hepatocytes^[5].
Alisol B 23-acetate (5-20 μM; 30 min before antigen challenge) inhibits IgE/antigen-mediated β-hexosaminidase release in RBL-2H3 mast cells in a concentration-dependent manner^[14].
In Vivo:Alisol B 23-acetate (2.56 mg/kg; p.o.; once daily; 90 days) activates hepatic FXR-BSEP signaling in ovariectomized LDLR^-/- mice, increases fecal cholesterol and bile acid excretion, reduces liver lipid deposition, and ameliorates atherosclerotic lesions^[5].
Alisol B 23-acetate (50-100 mg/kg; p.o.) inhibits IgE-mediated vascular permeability and ear swelling in ICR mouse passive cutaneous anaphylaxis (PCA) model^[7].
Alisol B 23-acetate (15-30 mg/kg; p.o.; daily; 9 weeks) reduces serum TG, IL-12, IFN-γ, increases HDL-C, and promotes aortic cholesterol efflux gene expression in ApoE^-/- atherosclerotic mice^[8].
Alisol B 23-acetate (10-40 mg/kg; p.o.; 30 days) suppresses TLR4/NOX2 pathway, reducing myocardial inflammation and ROS production in LPS-induced cardiac dysfunction mice^[9].
Alisol B 23-acetate (15-60 mg/kg; p.o.; daily; 4 weeks) ameliorates hepatic steatosis, inflammation, and fibrosis, and activates FXR target genes in MCD-induced NASH mice^[10].
Alisol B 23-acetate (12.5-50 mg/kg; p.o.; once daily; 7 days) promotes liver regeneration in mice after partial hepatectomy via activating farnesoid X receptor^[11].
Alisol B 23-acetate (10-40 mg/kg; p.o.; once daily; 7 days) alleviates hepatotoxicity in a dose-dependent manner in CCl₄ (HY-Y0298)-induced liver injury mice^[12].
Alisol B 23-acetate (60 mg/kg; i.p.; 30 min before sensitization/challenge) reduces airway hyperresponsiveness and decreases IL-13 and eosinophils in BALF in OVA-induced allergic asthma BALB/c mice^[14].